ASCO GU: Bristol Myers touts first-in-class Opdivo win in muscle-invasive bladder cancer

In the PD-1/L1 field, Merck & Co.’s Keytruda, Roche’s Tecentriq, and Pfizer and Merck KGaA’s Bavencio all have their clinical wins in different bladder cancer populations. Now, Bristol Myers Squibb’s Opdivo has one of its own.

In high-risk muscle-invasive urothelial carcinoma, the use of Opdivo after surgery cut patients’ risk of disease returning or death by 30% over placebo. The data was released for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium.